{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-009393","form_type":"8-K","ticker":"OBIO","cik":"0001814114","company_name":"Orchestra BioMed Holdings, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.989244+00:00","generated_at":"2026-05-27T02:49:21.412069+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Orchestra BioMed appoints former Medtronic SVP Chris Cleary to board; Dr. Eric Rose resigns as director","bullets":["Chris Cleary appointed as Class II independent director effective Jan 30, 2025; board expanded to nine.","Cleary was Medtronic SVP of Corporate Development, led $50B Covidien acquisition and $6B asset sale to Cardinal Health.","Cleary previously helped shape Orchestra BioMed's AVIM therapy strategic collaboration with Medtronic.","Eric Rose resigned as director Feb 3, 2025; remains as Emeritus Board Member and Strategic Advisor.","Board expected to decrease to eight members following Rose resignation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-009393","json":"https://secwatch.observer/filing/0001104659-25-009393.json","markdown":"https://secwatch.observer/filing/0001104659-25-009393.md","text":"https://secwatch.observer/filing/0001104659-25-009393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1814114/000110465925009393/0001104659-25-009393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1814114/000110465925009393/tm255461d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:49:21.412069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6769d41196","claim":"Chris Cleary was appointed as Class II director at Orchestra BioMed Holdings, Inc..","evidence_excerpt":"appointed Chris Cleary to serve as a Class II director, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465925009393/0001104659-25-009393-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"},{"claim_id":"be801f1674","claim":"Eric Rose resigned as director at Orchestra BioMed Holdings, Inc..","evidence_excerpt":"On February 3, 2025, Eric Rose, M.D., notified the Company of his resignation from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465925009393/0001104659-25-009393-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}